Avecho Biotechnology Welcomes New Board Expertise
Company Announcements

Avecho Biotechnology Welcomes New Board Expertise

Avecho Biotechnology Limited (AU:AVE) has released an update.

Avecho Biotechnology Limited has announced the appointment of Kathy Connell as a Non-Executive Director, bringing her extensive experience in healthcare and biotechnology to the company’s board. Connell’s background includes impactful roles at Johnson & Johnson and Sanofi, where she executed deals worth over $US1B, and her leadership has been recognized with awards such as the BioMelbourne Network’s Woman of the Year. Her expertise is expected to be valuable as Avecho advances into a critical phase of clinical trials and seeks to secure lucrative licensing agreements for its proprietary drug delivery system, TPM.

For further insights into AU:AVE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskAvecho Biotechnology Expands Trials and Manufacturing
TipRanks Australian Auto-Generated NewsdeskAvecho Biotech Reports Decreased Revenue and Rising Losses
TipRanks Australian Auto-Generated NewsdeskAvecho Biotech Advances Insomnia Treatment Trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App